Are AstraZeneca plc & Thomas Cook Group plc ‘Screaming Buys’?

Should you buy AstraZeneca plc (LON: AZN) and Thomas Cook Group plc (LON: TCG) right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the long run, all companies encounter highly challenging periods. They can be due to external factors such as a weakening in demand for a particular product or a slowdown in the wider economy. They can also be caused by internal challenges, such as poor planning and a strategy which ultimately leads to disappointing top and bottom line performance.

Either way, it normally has a very negative impact on a company’s share price and, while the effects can be horrific for investors, it also presents a very appealing buying opportunity. That’s because if the company can either adopt a better strategy or the external factors improve, capital gains could prove to be very enticing.

One company which has endured a very tough period is AstraZeneca (LSE: AZN). Its problems have largely been its own making, with the company failing to develop sufficient new drugs and put in place a suitable pipeline to overcome the inevitable loss of patents on key, blockbuster drugs. Furthermore, it also failed to use its cash in the most efficient manner; favouring a share buyback programme ahead of investing in research and development capabilities.

The result has been a severe decline in profitability, with AstraZeneca’s earnings per share expected to be just 62% of their 2011 level when the company reports its 2015 full-year results. However, AstraZeneca appears to now be making all of the right moves through which to mount a successful comeback, with an ambitious acquisition programme breathing new life into the company’s pipeline.

Clearly, it will inevitably take time to post positive profit growth. However, it seems likely to do so over the medium term which makes it current price to earnings (P/E) ratio of 16.1 seem hugely appealing.

Similarly, Thomas Cook (LSE: TCG) has also endured a troubled past, with the company becoming a loss-making entity in the period 2011 to 2014. This had a disastrous impact on the company’s share price, with it falling to a low of 13p in 2012 and there being major concerns about whether it would survive its difficult trading period.

However, now that the economic outlook is improved Thomas Cook is moving from strength to strength. Today’s results show that the company has made its first annual profit in five years despite the negative impact on demand for its holidays caused by the terrorist incidents of recent months. And, with the winter season already being 58% sold, it appears to be well-placed to deliver continued strong performance moving forward.

Looking ahead, Thomas Cook is forecast to increase its earnings by 28% next year which, alongside a P/E ratio of 9.4, puts it on a price to earnings growth (PEG) ratio of just 0.3. This indicates that its shares have very appealing capital gains prospects – especially since the UK and European economies are showing signs of life and are set to benefit from a continued loose monetary policy in future years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Looking for a £750 monthly passive income? Here’s how much it takes

The idea of buying dividend shares for their passive income potential can sound promising. How might the nuts and bolts…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

£20,000 in this ISA portfolio would generate £1,400 in passive income

Ben McPoland presents a ready-made Stocks and Shares ISA portfolio containing five UK names that as a group currently yield…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The most underrated stock in the FTSE 100?

Nobody seems to like the FTSE 100’s water utilities. But could Severn Trent be the biggest opportunity that investors aren’t…

Read more »

a couple embrace in front of their new home
Investing Articles

£1,000 now buys 1,075 Taylor Wimpey shares. Worth it for the 8% dividend yield?

There’s a massive dividend yield on offer from his well-known UK housebuilder right now. But what are the risks for…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

Want to invest in SpaceX, Revolut, and TikTok? Consider buying this FTSE 100 stock

Ben McPoland thinks this FTSE 100 investment trust is a top stock to consider buying to gain exposure to the…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s my Stocks and Shares ISA plan for 2026/27

Stephen Wright has a clear plan when it comes to investing in his Stocks and Shares ISA. But do the…

Read more »

Two elderly people relaxing in the summer sunshine Box Hill near Dorking Surrey England
Investing Articles

Where to look for safety in today’s stock market?

Stephen Wright has been looking for safety in a specific place in today’s stock market. And Warren Buffett’s firm has…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

This 5-share ISA could deliver an amazing second income of £762 a month

As the world’s stock markets plunge, many yields are rising. James Beard looks at five shares that could generate an…

Read more »